3/30/2023 7:13:18 AM
Omega Therapeutics Announces Clinical Supply Deal To Evaluate Combination Of OTX-2002 And Atezolizumab In Hepatocellular Carcinoma
11/8/2022 7:11:23 AM
Omega Therapeutics Q3 Net Loss $25.8 Mln Vs. Net Loss $18.5 Mln Last Year
11/2/2022 7:14:49 AM
Omega Therapeutics Gets Orphan Drug Designation For OTX-2002 For Treatment Of Hepatocellular Carcinoma
8/4/2022 7:53:41 AM
Omega Therapeutics Q2 Net Loss Widens To $25.9 Mln From $15.4 Mln Last Year
6/15/2022 7:06:30 AM
Omega Therapeutics Submits IND Application For OTX-2002 For The Treatment Of Hepatocellular Carcinoma
4/29/2022 7:04:04 AM
Omega Therapeutics Names Joshua Reed As CFO, Effective May 23
3/11/2022 10:15:35 AM
Wedbush Is Raising Omega Therapeutics, Inc. (OMGA) Q1 22 Estimate To -0.51 From -0.83
3/10/2022 7:29:13 AM
Omega Therapeutics Q4 Net Loss $20.9 Mln, Vs. Loss $9.5 Mln Prior Year
11/12/2021 8:15:22 PM
Wedbush Reiterates Omega Therapeutics, Inc. (OMGA) At Outperform With $36 Price Target
11/12/2021 8:13:29 PM
Wedbush Is Lowering Omega Therapeutics, Inc. (OMGA) FY22 Estimate To -3.62 From -3.31
11/12/2021 8:13:15 PM
Wedbush Is Increasing Omega Therapeutics, Inc. (OMGA) Q4 22 Estimate To -0.83 From -0.88
11/12/2021 8:13:01 PM
Wedbush Is Cutting Omega Therapeutics, Inc. (OMGA) Q3 22 Estimate To -1.05 From -0.90
11/12/2021 8:12:47 PM
Wedbush Is Lowering Omega Therapeutics, Inc. (OMGA) Q2 22 Estimate To -0.94 From -0.80
11/12/2021 8:12:31 PM
Wedbush Is Lowering Omega Therapeutics, Inc. (OMGA) Q1 22 Estimate To -0.83 From -0.71
11/12/2021 8:12:20 PM
Wedbush Is Lowering Omega Therapeutics, Inc. (OMGA) FY21 Estimate To -3.84 From -3.07
11/12/2021 8:12:06 PM
Wedbush Is Lowering Omega Therapeutics, Inc. (OMGA) Q4 21 Estimate To -0.72 From -0.61
11/10/2021 7:15:49 AM
Omega Therapeutics Q3 Loss Per Share $0.57 Vs Loss $1.97 Last Year
9/10/2021 7:36:17 AM
Omega Therapeutics Q2 Loss Per Share $3.36 Vs Loss $1.58 Last Year